ARKG vs RSP

ARK Genomic Revolution ETF vs Invesco S&P 500 Equal Weight ETF

Quick take
  • RSP has the lower expense ratio at 0.20% vs 0.75% for ARKG.
  • RSP pays a higher dividend yield (1.51%).

Side-by-side metrics

MetricARKGRSP
Expense ratio
Annual fee. Lower is better.
0.75%0.20%
Dividend yield
Trailing 12-month yield.
0.00%1.51%
AUM
Assets under management — bigger funds are typically more liquid.
$1.73B$93.66B
YTD return
44.53%11.67%
1-year return
3-year return
Annualized.
5-year return
Annualized.
10-year return
Annualized.
Beta (3Y)
Volatility relative to the market. Closer to 1 = market-like.
2.380.85
P/E ratio
22.17
Last price
$43.17$214.01
Inception
Issuer
ARKInvesco

ARKG top holdings

Top holdings · ARKG
TWSTTwist Bioscience Corp9.15%
TEMTempus AI Inc Class A common stock7.64%
ABSIAbsci Corp7.01%
TXG10x Genomics Inc Ordinary Shares - Class A7.00%
CRSPCRISPR Therapeutics AG6.56%
PSNLPersonalis Inc6.19%
BEAMBeam Therapeutics Inc4.34%
GHGuardant Health Inc4.28%
NTRANatera Inc4.11%
ILMNIllumina Inc3.98%
Sector breakdown · ARKG
Healthcare100.0%

RSP top holdings

Top holdings · RSP
MRNAModerna Inc0.29%
GLWCorning Inc0.29%
AMATApplied Materials Inc0.28%
KLACKLA Corp0.27%
TERTeradyne Inc0.27%
SNDKSanDisk Corp Ordinary Shares0.27%
GEVGE Vernova Inc0.26%
LRCXLam Research Corp0.26%
TECHBio-Techne Corp0.26%
UALUnited Airlines Holdings Inc0.26%
Sector breakdown · RSP
Real Estate5.9%
Consumer Cyclical10.9%
Basic Materials3.9%
Consumer Defensive6.3%
Technology17.3%
Communication Services4.0%
Financial Services13.9%
Utilities6.3%
Industrials15.7%
Energy3.8%
Healthcare12.0%

About ARKG

ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.

About RSP

RSP (Invesco S&P 500 Equal Weight ETF) is S&P 500 with each stock equally weighted. Managed by Invesco, the fund carries $93.7B in assets under management, an expense ratio of 0.20%, a dividend yield of 1.51%. Its largest holding is Moderna Inc (MRNA), which represents 0.3% of the portfolio. Real Estate is the fund's largest sector exposure at 5.9%.